
The latest announcement is out from Werewolf Therapeutics ( ($HOWL) ). On November 9, 2026, Werewolf announced clinical data for WTX-124 and WTX-330 presented at the Society for Immunotherapy of
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| HOWL | Werewolf Therapeutics | 0.99 | 0.10 | 11.47% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.99 | +11.47% |

The latest announcement is out from Werewolf Therapeutics ( ($HOWL) ). On November 9, 2026, Werewolf announced clinical data for WTX-124 and WTX-330 presented at the Society for Immunotherapy of

Werewolf Therapeutics (HOWL) announced new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 (IL-2) and Interleukin-12

Werewolf Therapeutics, Inc. ($HOWL) announced an update on their ongoing clinical study. Werewolf Therapeutics, Inc. (HOWL) has completed a Phase I/Ib study titled “A Multicenter Phase I/Ib Dose Escalation and

StablecoinX Inc., Jupiter Neurosciences, and Werewolf Therapeutics are among the top penny stocks to watch on August 25, according to TipRanks’ Penny Stock Screener tool. A penny stock typically trades below $5 per share

The latest update is out from Werewolf Therapeutics ( ($HOWL) ). On August 21, 2026, Werewolf Therapeutics and Ambros Therapeutics signed a definitive all‑stock merger agreement under which Ambros will

Werewolf Therapeutics stock was up 127.23% on Friday alongside news that the company will combine with Ambros Therapeutics in an all-stock deal.

Stock futures are higher as investors attempt to recover from Thursday’s sharp selloff. Despite the rebound, all three major indexes remain on track for weekly losses, with the Dow facing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing

Werewolf Therapeutics ( ($HOWL) ) just unveiled an update. On August 14, 2026, Werewolf Therapeutics entered into an asset purchase agreement with EMD Serono Research & Development Institute under which

Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Werewolf Therapeutics, Inc. faces a significant listing risk after receiving a Nasdaq deficiency
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 25, 2027TBA | $51.03M | ― | ― | 0.03 | -1.79 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.